Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Equity (2021 - 2023)

Historic Return on Equity for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to 1.35%.

  • Candel Therapeutics' Return on Equity fell 7200.0% to 1.35% in Q3 2023 from the same period last year, while for Sep 2023 it was 1.35%, marking a year-over-year decrease of 7200.0%. This contributed to the annual value of 0.63% for FY2022, which is 6400.0% up from last year.
  • Candel Therapeutics' Return on Equity amounted to 1.35% in Q3 2023, which was down 7200.0% from 1.03% recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Return on Equity registered a high of 0.41% during Q4 2021, and its lowest value of 2.43% during Q3 2021.
  • Its 3-year average for Return on Equity is 0.93%, with a median of 0.71% in 2022.
  • As far as peak fluctuations go, Candel Therapeutics' Return on Equity surged by 18100bps in 2022, and later plummeted by -7200bps in 2023.
  • Candel Therapeutics' Return on Equity (Quarter) stood at 0.41% in 2021, then tumbled by -74bps to 0.71% in 2022, then tumbled by -91bps to 1.35% in 2023.
  • Its last three reported values are 1.35% in Q3 2023, 1.03% for Q2 2023, and 0.81% during Q1 2023.